Epcoritamab: Clinical Trials

16 trials of Epcoritamab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 active not recruiting, 7 recruiting, 1 not yet recruiting, 1 terminated. 16 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Active not recruiting 7, Recruiting 7, Not yet recruiting 1, Terminated 1
Phase 29Active not recruiting 5, Recruiting 3, Terminated 1

Follow Epcoritamab: new trials by email Literature Review of Epcoritamab trials Research Report on Epcoritamab

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 1Not yet recruitingJonsson Comprehensive Cancer Center202026-12-082026-07-20
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Epcoritamab, Glofitamab, External Beam Radiation Therapy - Diffuse Large B Cell Lymphoma
Phase 1RecruitingUniversity of Utah122026-06-012026-06-04
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
ibrutinib, Epcoritamab - Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma
Phase 1RecruitingMemorial Sloan Kettering Cancer Center262025-08-132026-07-14
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
epcoritamab - Leukemia, Chronic Lymphocytic, Richter Syndrome
Phase 1Active not recruitingNational Heart, Lung, and Blood Institute (NHLBI)52025-07-182026-11-09
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder
Phase 1RecruitingTimothy Voorhees262025-06-162026-09-24
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma
Phase 1 / Phase 2RecruitingYazeed Sawalha382025-04-022026-08-25
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin - Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Phase 1RecruitingTaylor Brooks202025-01-142026-06-25
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Epcoritamab, Venetoclax - CLL/SLL
Phase 1 / Phase 2RecruitingStichting Hemato-Oncologie voor Volwassenen Nederland1122024-04-152026-10-05
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
BMS-986458, Rituximab, Glofitamab/Obinutuzumab - Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingBristol-Myers Squibb4602023-12-292026-10-23
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Epcoritamab - Non-hodgkin Lymphoma
Phase 1Active not recruitingGenmab172022-10-042026-09-11
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Epcoritamab, Cyclophosphamide, Rituximab - B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab492022-03-102026-11-04
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax - Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab1942020-11-252026-11-04
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab5432020-11-032026-11-03
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab782020-08-202026-11-04
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2TerminatedGenmab462020-03-132024-10-24
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Epcoritamab - DLBCL, High-grade B-cell Lymphoma (HGBCL)
Phase 1 / Phase 2Active not recruitingGenmab6662018-06-262026-11-04

Conditions studied

Lymphoma, Large B-Cell, Diffuse (7)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (5)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Lymphoma, Follicular (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Lymphoma, B-Cell (2)  ·  Neoplasms (2)  ·  Cytokine Release Syndrome (1)  ·  Leukemia (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Recurrence (1)

Sponsors

Genmab (7)  ·  Bristol-Myers Squibb (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Stichting Hemato-Oncologie voor Volwassenen Nederland (1)  ·  Taylor Brooks (1)  ·  Timothy Voorhees (1)  ·  University of Utah (1)  ·  Yazeed Sawalha (1)

Countries

United States (13)  ·  Netherlands (6)  ·  Spain (6)  ·  Australia (5)  ·  Belgium (5)  ·  Denmark (5)  ·  France (5)  ·  Germany (5)  ·  Italy (5)  ·  Czechia (3)  ·  Japan (3)  ·  South Korea (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  China (2)

Top investigators

Adrian U Wiestner, M.D. (1)  ·  Christian Grommes, MD (1)  ·  Sven De Vos (1)  ·  Taylor Brooks, MD (1)  ·  Timothy J Voorhees, MD (1)  ·  Yazeed Sawalha (1)

Results publications

PMID 42411504, PMID 42541678, PMID 34508654, PMID 36548927, PMID 38151388, PMID 38889737, PMID 39322711, PMID 39792928, PMID 40472301, PMID 40632620, PMID 40920572, PMID 41380698, PMID 41670385, PMID 41784015, PMID 42431612, PMID 42622258, PMID 42660129

NIH funding

2023 (4), 2017 (1), 2019 (1), R01CA308586 (1)